Licensing status

Publication and contact information

Hepatic disease

Liver disease

High mobility group box 1 (HMGB1)

Studies in patient samples and mice suggest inhibiting HMGB1 could help treat alcoholic liver disease. In samples from patients with alcoholic liver disease or in mice fed an ethanol diet, expression of the proinflammatory cytokine HMGB1 was greater than that in healthy individuals or mice fed an ethanol-free diet. In ethanol-fed mice, Hmgb1 knockout protected against the development of alcoholic liver disease. Next steps include studies to understand the roles of specific HMGB1 isoforms in liver disease.
Asahi Kasei Pharma Corp. markets Recomodulin, a soluble form of recombinant human thrombomodulin-a that promotes degradation of HMGB1, to treat disseminated intravascular coagulation in sepsis. The drug is also in Phase III testing for severe sepsis with coagulopathy.

SciBX 7(28); doi:10.1038/scibx.2014.827
Published online July 24, 2014

Patent and licensing status undisclosed

Ge, X. et al. J. Biol. Chem.; published online June 13, 2014;
Contact: Natalia Nieto, Icahn School of Medicine at Mount Sinai, New York, N.Y.